| 1D | One-Dimensional |
| 2D | Two-Dimensional |
| 4-HPAA | 4-Hydroxyphenylacetate |
| Ace | Acetone |
| ACEi | Angiotensin-Converting Enzyme inhibitors |
| ACE-R | Revised Addenbrooke’s Cognitive Test |
| AChE | Acetylcholinesterase |
| AnCoa | Anticoagulants |
| ARA | Angiotensin II Receptor Antagonists |
| AUC | Area Under the Curve |
| AUROC | Area Under the Receiver Operating Characteristic Curve |
| BAA | Beta-Adrenergic Antagonists |
| BMI | Body Mass Index |
| BP | Blood Pressure |
| CCB | Calcium Channel Blockers |
| Cit | Citrate |
| CST | Chi-Squared Test |
| CVMD | Cardiovascular or Metabolic Diseases |
| DBP | Diastolic Blood Pressure |
| DIU | Diuretics |
| DPP-4 | Dipeptidyl peptidase-4 |
| EBIcohort | Elders from Beira Interior cohort |
| FET | Fisher’s Exact Test |
| GDS | Global Deterioration Scale |
| HDL cholesterol | High-Density Lipoprotein cholesterol |
| HT | Hypertension |
| HTall | Group consisting of participants diagnosed with hypertension (with and without comorbidities) |
| HTo | Subgroup (inside HTall group) of participants diagnosed with hypertension, without any cardiovascular or metabolic comorbidities. |
| HTdl | Subgroup of participants diagnosed with hypertension + dyslipidemia, without other cardiovascular or metabolic comorbidities (namely, diabetes or cardiovascular diseases) |
| HTdb | Subgroup of participants diagnosed with hypertension + diabetes, without other cardiovascular or metabolic comorbidities (namely, dyslipidemia or cardiovascular diseases) |
| HTcd | Subgroup of participants diagnosed with hypertension + one cardiovascular disease (heart failure, arrhythmia, or history of acute myocardial infarction), without other cardiovascular or metabolic comorbidities (namely dyslipidemia or diabetes) |
| HTdb•dl | Subgroup of participants diagnosed with hypertension + dyslipidemia + diabetes, without other cardiovascular or metabolic comorbidities (namely, cardiovascular diseases) |
| HTcd•dl | Subgroup of participants diagnosed with hypertension + dyslipidemia + one cardiovascular disease (heart failure, arrhythmia, or history of acute myocardial infarction), without other cardiovascular or metabolic comorbidities (namely, diabetes) |
| HTcd•db | Subgroup of participants diagnosed with hypertension + diabetes + one cardiovascular disease (heart failure, arrhythmia, or history of acute myocardial infarction), without other cardiovascular or metabolic comorbidities (namely, dyslipidemia) |
| JRES | J-RESolved spectroscopy |
| KWT | Kruskal–Wallis test |
| LDL cholesterol | Low-Density Lipoprotein cholesterol |
| LTCF | Long-Term Care Facilities |
| MAO | Monoamine oxidase |
| MG | Methylglutaconate |
| MMSE | Mini-Mental State Examination |
| MWT | Mann–Whitney Test |
| N-IVG | N-Isovaleroylglycine |
| NMDA | N-Methyl-D-Aspartate |
| NMR | Nuclear Magnetic Resonance |
| NOESY | Nuclear Overhauser Effect Spectroscopy |
| NT | Normotensive |
| OWAT | One-way ANOVA test |
| Oxa | Oxaloacetate |
| Phe | Phenylalanine |
| Pyr | Pyridoxate |
| S.E. | Standard Error |
| Sar | Sarcosine |
| SBP | Systolic Blood Pressure |
| STT | Student t-test |
| TOCSY | Total Correlation Spectroscopy |
| WHO | World Health Organization |